insomnia

The new analysis of a Pear Therapeutics-based randomized controlled trial came alongside another investigation that spotted early signs of treatment dropout.

Somryst, a prescription digital therapeutic combining cognitive behavioral therapy and personalized sleep restriction, is the first software product to put the FDA's early Precertification Program framework through its paces. 

Among a study group of 1,711 users, use of the Sleepio app appeared to drive improvements in self-reported functional health, psychological wellbeing, and sleep-related quality of life.